Elmind Capital LP Buys New Holdings in Tyra Biosciences, Inc. $TYRA

Elmind Capital LP acquired a new stake in Tyra Biosciences, Inc. (NASDAQ:TYRA) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor acquired 20,000 shares of the company’s stock, valued at approximately $638,800,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. 5AM Venture Management LLC acquired a new position in shares of Tyra Biosciences during the second quarter worth approximately $32,875,778,000. PDT Partners LLC bought a new position in shares of Tyra Biosciences in the 2nd quarter valued at about $820,000. Canada Pension Plan Investment Board acquired a new stake in shares of Tyra Biosciences during the 2nd quarter worth approximately $230,000. Legal & General Group Plc acquired a new stake in shares of Tyra Biosciences during the 2nd quarter worth approximately $575,000. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of Tyra Biosciences during the second quarter worth approximately $1,416,000. 84.14% of the stock is currently owned by institutional investors and hedge funds.

Tyra Biosciences Price Performance

Tyra Biosciences stock opened at $26.69 on Wednesday. The company’s 50-day moving average is $29.68 and its 200-day moving average is $32.27. The firm has a market capitalization of $1.59 billion, a PE ratio of -11.12 and a beta of 0.77. Tyra Biosciences, Inc. has a fifty-two week low of $11.70 and a fifty-two week high of $40.65.

Tyra Biosciences (NASDAQ:TYRA) last issued its earnings results on Tuesday, August 4th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.04). As a group, analysts expect that Tyra Biosciences, Inc. will post -2.74 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have commented on TYRA. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tyra Biosciences in a research report on Friday, July 17th. HC Wainwright reaffirmed a “buy” rating and issued a $45.00 price target on shares of Tyra Biosciences in a research note on Thursday, May 14th. Wolfe Research began coverage on shares of Tyra Biosciences in a report on Tuesday, May 19th. They set a “peer perform” rating for the company. Bank of America increased their target price on shares of Tyra Biosciences from $37.00 to $42.00 and gave the stock a “buy” rating in a report on Wednesday, June 10th. Finally, JonesTrading started coverage on shares of Tyra Biosciences in a report on Wednesday, June 17th. They issued a “buy” rating and a $56.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $46.90.

Tyra Biosciences Profile

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.